Dupilumab Resolves Airway Mucus Plugs and Reduces Radiodensity in Asthma

In patients with moderate-to-severe asthma, chronic airway inflammation often leads to the formation of occlusive mucus plugs that contribute to persistent airflow obstruction and increased exacerbation risk [1, 2]. These plugs are frequently associated with type 2 inflammation, characterized by elevated blood eosinophils and fractional exhaled nitric oxide [3, 4]. While interleukin-4 and interleukin-13 antagonists like dupilumab have demonstrated efficacy in improving forced expiratory volume and reducing the need for oral corticosteroids, the physical resolution of these airway obstructions remains a primary clinical goal [5, 6]. Traditional assessments have focused on global lung function, yet localized ventilation defects often persist despite standard therapy [2, 7]. A new study now offers fresh insights into the longitudinal behavior and structural changes of individual mucus plugs under biologic treatment.